Bioxcel Therapeutics Q1 2022 Earnings Report
Key Takeaways
BioXcel Therapeutics reported a net loss of $31.5 million for the first quarter of 2022. The company received FDA approval for IGALMI and extended its cash runway into 2025 with a $260 million strategic financing.
Received FDA approval of IGALMIâ„¢ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults
Top-line data readout in Q4 2022/early Q1 2023 for TRANQUILITY II Phase 3 trial evaluating BXCL501 in acute treatment of agitation associated with Alzheimer’s disease
Extended cash runway into 2025 with $260 million strategic financing for IGALMI commercial launch and clinical and regulatory milestones
U.S. national salesforce deployment to commence on May 23, 2022
Bioxcel Therapeutics
Bioxcel Therapeutics
Forward Guidance
The press release includes forward-looking statements regarding the commercialization and medical affairs plans for IGALMI, timing and data from clinical trials for BXCL501 and BXCL701, the timing of the Company’s MAA application for BXCL501, and future financial and operational results.